T1	Participants 243 282	patients with moderate-to-severe asthma
T2	Participants 884 1156	Symptomatic patients (n = 428) with FEV1 of 50-85% predicted and increased symptom scores or reliever use during run-in were randomly allocated to receive either Salm/FP (50/250 microg bd) via a single Diskus inhaleror Form+Bud (12+800 microg bd) via separate Turbuhalers.
T3	Participants 1579 1633	Salm/FP group (0.472) compared with the Form+Bud group
